Vaxcyte advances second stage of Phase 2 study evaluating VAX-31
Vaxcyte (PCVX) announced that the first study participants have been dosed in the second and final stage of the ongoing Phase 2 study of VAX-31 in healthy infants. Advancement to Stage 2 follows a ...
Vaxcyte enters final stage of Phase II pneumococcal vaccine trial in infants
VAX-31’s safety, tolerability, and immunogenicity are being assessed in this trial on healthy infants. Vaxcyte anticipat ...
Asia News Network1d
Brunei introduces pneumococcal vaccine for infants, children
With this addition, the Sultanate's immunisation programme now includes 12 vaccines to prevent 12 vaccine-preventable diseases. Vaccinations under the programme are provided free of charge at Maternal ...
Vaxcyte advances to final stage in infant vaccine study
SAN CARLOS, Calif. - Vaxcyte, Inc. (NASDAQ:PCVX), a vaccine innovation company valued at $10.78 billion, has announced the commencement of the final stage of its Phase 2 study for VAX-31, a ...
Vaxcyte Advances to Second Stage of Ongoing Phase 2 Study Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease in Infants
Advancement to Stage 2 of Infant Study Supported by Review of Stage 1 Safety and Tolerability Data ---- Company Expects to Announce VAX-31 ...
Hosted on MSN4d
MRK Gets Positive CHMP Nod for 21-Valent Pneumococcal Jab Capvaxive
Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of its 21-valent pneumococcal conjugate ...